RxDoctor Payments Data

Ryan Devine, DO

Hematology & Oncology · Stuart, FLNPI 1568622207

Payments from drug & device makers

$117,617in general payments, 2019–2025

Across 607 payments — averaging $193.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$107K
  • Pfizer$901
  • E.r. Squibb & Sons, L.L.C.$835
  • Merck$618
  • Johnson & Johnson$457
  • Seagen Inc.$425
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$1501%
  • Food & beverage$11,46497%
  • Education$2202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)61$107,248
Pfizer66$901
E.r. Squibb & Sons, L.L.C.43$835
Merck36$618
Johnson & Johnson(2 entities)27$457
Seagen Inc.17$425
Amgen27$416
Lilly USA, LLC26$416
Daiichi Sankyo Inc.17$404
Astellas Pharma US Inc18$358
Sirtex Medical Inc10$322
GSK16$318
Bristol Myers Squibb15$279
Sanofi15$273
Novartis14$248
Jazz Pharmaceuticals Inc.14$244
AbbVie12$241
Dova Pharmaceuticals14$233
Genentech USA, Inc.11$201
Bayer11$200
Incyte Corporation11$194
Eisai Inc.9$186
Puma Biotechnology, Inc.11$179
Regeneron Healthcare Solutions, Inc.4$177
Janssen Scientific Affairs, LLC1$150
Ferring Pharmaceuticals Inc.5$149
Coherus Oncology, Inc.5$145
Exelixis Inc.7$126
Novocure Inc.1$125
Ipsen Biopharmaceuticals, Inc6$119
Array Biopharma Inc6$114
Karyopharm Therapeutics Inc.6$104
Pharmacyclics LLC, An Abbvie Company4$75
Alnylam Pharmaceuticals Inc.3$71
Deciphera Pharmaceuticals Inc.3$68
TG Therapeutics, Inc.3$64
Foundation Medicine, Inc.4$63
Boehringer Ingelheim3$53
Tolmar Pharmaceuticals, Inc.3$53
Pharmaessentia USA Corporation2$51
Takeda Pharmaceuticals U.S.A., Inc.2$51
Taiho Oncology, Inc.2$42
Recordati_rare_diseases_inc.2$41
Sobi, Inc2$41
Mylan Institutional Inc.2$39
Advanced Accelerator Applications2$36
Kyowa Kirin, Inc.2$35
Beigene USA, Inc.2$34
Organon2$32
EMD Serono, Inc.2$32
Gilead2$31
Global Blood Therapeutics, Inc.2$27
Epizyme, Inc.2$26
Adaptive Biotechnologies Corporation1$24
Emmaus Medical, Inc.1$23
EUSA Pharma (US) LLC1$22
Myriad Genetic Laboratories, Inc.1$22
Clovis Oncology, Inc.1$22
Sun Pharmaceutical Industries Inc.1$18
Helsinn Therapeutics (U.S.), Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$117,617 in reported general payments places this provider in the 65th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$158,037
Medicare patients
340
Services billed
1,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate57$1,056,877
Lenalidomide43$663,050
ErleadaApalutamide21$310,690
NubeqaDarolutamide16$220,042
CalquenceAcalabrutinib Maleate11$84,969
OrgovyxRelugolix25$81,031
Abiraterone Acetate50$50,306
EliquisApixaban59$43,855
XareltoRivaroxaban14$12,190
Acyclovir51$823
Hydroxyurea33$729
Prednisone94$575
Ondansetron Hcl34$544
Levofloxacin28$432
Dexamethasone23$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$194$1,056,87757 claims
Johnson & JohnsonErleada, Xarelto$457$322,88035 claims
BayerNubeqa$200$220,04216 claims
AstraZenecaCalquence$107,248$84,96911 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$150$50,30650 claims
PfizerEliquis$901$43,85559 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →